Labcorp expands oncology portfolio to improve patient care and advance cancer research

New test offerings target solid tumors and hematologic malignancies enhanced biopharma services support accelerated clinical trials and companion diagnostic development burlington, n.c. , may 30, 2025 /prnewswire/ -- labcorp (nyse: lh), a global leader of innovative and comprehensive laboratory services, announced today the expansion of its precision oncology portfolio.
LH Ratings Summary
LH Quant Ranking